Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-drug conjugates - Sorrento Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Sorrento Therapeutics

Alternative Names: AfDCs - Sorrento Therapeutics; Antibody-formulated drug conjugates - Sorrento Therapeutics; STI-0602; ZV05 ADCs - Sorrento Therapeutics

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sorrento Therapeutics
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Proto-oncogene protein c-met modulators; Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer; Haematological malignancies; Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 28 May 2020 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
  • 24 Mar 2020 Sorrento Therapeutics plans a phase I trial for Amyloidosis (Parenteral) in August 2020 (NCT04316442)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top